EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial

Sophie Dupuis-Girod iD, Sophie Rivière, Christian Lavigne, Anne-Emmanuelle Fargeton, Brigitte Gilbert-Dussardier, Vincent Grobost iD, Vanessa Leguy-Seguin, Hélène Maillard, Shirine Mohamed, Evelyne Decullier, Adeline Roux, Lorraine Bernard und 14 weitere

Journal of Internal Medicine · 2023

DOI: 10.1111/joim.13714 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Internal Medicine, 2023. Verfasst von Sophie Dupuis-Girod und 25 weiteren Autor:innen. Beteiligte Einrichtung: Service de Génétique et centre de référence de la maladie de Rendu-Osler, Hôpital Femme-Mère-Enfants, Hospices Civils de Lyon, Bron, France. Hauptthemen laut MEDLINE: Hemorrhage, Telangiectasia, Hereditary Hemorrhagic. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bevacizumab—a humanized monoclonal antibody—has been widely used to treat patients with hereditary hemorrhagic telangiectasia (HHT), but no randomized trial has yet been conducted.

Methods

This study is a double‐blind multicenter randomized phase 2 trial with a 1:1 active‐treatment‐to‐placebo ratio. We included patients over the age of 18 with a confirmed diagnosis and the need for at least four red blood cell (RBC) units transfused in the 3 months before study enrollment. Bevacizumab was administered at a dose of 5 mg/kg every 14 days with a total of six injections. The primary efficacy criterion was a decrease of at least 50% in the cumulative number of RBC units transfused in a 3‐month period before and after treatment.

Results

A total of 24 patients (12 in each group) were included and randomized at 4 different centers. In intention‐to‐treat analysis, 63.6% of patients (7/11) in the bevacizumab group versus 33.3% of patients (4/12) in the placebo group decreased the number of blood transfusions by at least 50% ( p = 0.22). Hemoglobin levels significantly improved at 6 months in the bevacizumab versus placebo group ( p = 0.02). The pharmacokinetics study revealed that patients with high exposure to bevacizumab had a significant decrease in RBC transfusions ( p = 0.03). Fifty‐nine adverse events were observed, 34 in the placebo arm versus 25 in the bevacizumab arm.

Conclusion

Though the present trial was underpowered, patients with HHT receiving bevacizumab required numerically fewer red blood cell transfusions than those receiving placebo, particularly those with high exposure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemorrhageTelangiectasia, Hereditary HemorrhagicAdultHumansMiddle AgedAntibodies, Monoclonal, HumanizedBevacizumabTreatment OutcomeDouble-Blind Method

Stichwörter der Autor:innen

bevacizumabhereditary hemorrhagic telangiectasiarare vascular diseasered blood cell transfusion

Substanzen

Antibodies, Monoclonal, HumanizedBevacizumab

Autor:innen und Institutionen

  • Service de Génétique et centre de référence de la maladie de Rendu-Osler, Hôpital Femme-Mère-Enfants, Hospices Civils de Lyon, Bron, France.
  • Inserm, CEA, Laboratory Biology of Cancer and Infection, Université Grenoble Alpes, Grenoble, France.
  • Service de Médecine Interne A, Centre Hospitalier Universitaire, Montpellier, France.
  • Service de médecine interne-Immunologie clinique, CHU d'Angers, Angers cedex 09, France.
  • Service de génétique médicale, CHU La Milétrie, Poitiers, France.
  • Service de Médecine Interne CHU Estaing, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.

ORCID-Profile: Sophie Dupuis-Girod, Vincent Grobost

Zitieren

APA

Dupuis-Girod, S., Rivière, S., Lavigne, C., Fargeton, A. E., Gilbert-Dussardier, B., Grobost, V., Leguy-Seguin, V., Maillard, H., Mohamed, S., Decullier, E., Roux, A., Bernard, L., Saurin, J. C., Saroul, N., Faure, F., Cartier, C., Altwegg, R., Laccourreye, L., Oberti, F., …, & Chinet, T. (2023). Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial. Journal of Internal Medicine. https://doi.org/10.1111/joim.13714

Vancouver

Dupuis-Girod S, Rivière S, Lavigne C, Fargeton AE, Gilbert-Dussardier B, Grobost V, et al. Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial. Journal of Internal Medicine. 2023. doi:10.1111/joim.13714

BibTeX
@article{DupuisGirod2023,
  author = {Dupuis-Girod, Sophie and Rivière, Sophie and Lavigne, Christian and Fargeton, Anne-Emmanuelle and Gilbert-Dussardier, Brigitte and Grobost, Vincent and Leguy-Seguin, Vanessa and Maillard, Hélène and Mohamed, Shirine and Decullier, Evelyne and Roux, Adeline and Bernard, Lorraine and Saurin, Jean-Christophe and Saroul, Nicolas and Faure, Frédéric and Cartier, Cesar and Altwegg, Romain and Laccourreye, Laurent and Oberti, Frédéric and Beaudoin, Marjolaine and Dhelens, Carole and Desvignes, Céline and Azzopardi, Nicolas and Paintaud, Gilles and Hermann, Ruben and Chinet, Thierry},
  title = {Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial},
  journal = {Journal of Internal Medicine},
  year = {2023},
  doi = {10.1111/joim.13714}
}
Kostenlos starten →